FDA
-
-
-
-
-
-
-
ProKidney secures FDA alignment on accelerated approval pathway for rilparencel
-
-
-
-
-
-
-
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
-
-
-
-
-
-
-
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
-
-
-
-
-
-
-
ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
-
-
-
-
-
-
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
-
-
-
-
-
-
-
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

